BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19849763)

  • 21. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
    Marcus R; Imrie K; Solal-Celigny P; Catalano JV; Dmoszynska A; Raposo JC; Offner FC; Gomez-Codina J; Belch A; Cunningham D; Wassner-Fritsch E; Stein G
    J Clin Oncol; 2008 Oct; 26(28):4579-86. PubMed ID: 18662969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
    Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.
    Harjunpää A; Taskinen M; Nykter M; Karjalainen-Lindsberg ML; Nyman H; Monni O; Hemmer S; Yli-Harja O; Hautaniemi S; Meri S; Leppä S
    Br J Haematol; 2006 Oct; 135(1):33-42. PubMed ID: 16925574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
    Czuczman MS
    Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of Rituximab-CHOP regimen in combination with granulocyte colony-stimulating factor in patients with follicular lymphoma.
    Niitsu N; Hayama M; Okamoto M; Khori M; Higashihara M; Tamaru J; Hirano M
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4077-82. PubMed ID: 15217942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A case of follicular lymphoma of the duodenum treated with the combined therapy of anti-CD20 antibody and chemotherapy].
    Isogai K; Yamamoto E; Yamaoka S; Tarasawa I; Murakami R; Morimoto I; Obata T; Mori M; Endo T; Imai K
    Nihon Shokakibyo Gakkai Zasshi; 2006 Mar; 103(3):301-9. PubMed ID: 16688961
    [No Abstract]   [Full Text] [Related]  

  • 27. [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy].
    Kakuta Y; Katoh T; Saitoh J; Yazawa K; Hosomi M; Itoh K
    Hinyokika Kiyo; 2006 Dec; 52(12):951-4. PubMed ID: 17252980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel treatment strategies in follicular lymphoma.
    Buske C; Dreyling H; Unterhalt M; Hiddemann W
    Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr virus-induced lymphoproliferative disorder after rituximab combined with CHOP therapy.
    Johnston A; Salles G; Espinouse D; Felman P; André P; Berger F; Coiffier B
    Clin Lymphoma Myeloma; 2008 Dec; 8(6):356-8. PubMed ID: 19064401
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment of primary non-Hodgkin's lymphoma of the vagina with chemotherapy.
    Engin H; Türker A; Abali H; Uner A; Günalp S
    Arch Gynecol Obstet; 2004 Mar; 269(3):208-10. PubMed ID: 12904985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Follicular lymphoma in two brothers].
    Asahi A; Okamoto S; Matsushita H; Hattori Y; Takayama N; Ikeda Y
    Rinsho Ketsueki; 2001 May; 42(5):408-13. PubMed ID: 11452461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [THP-adriamycin-based combination chemotherapy in the treatment of non-Hodgkin's lymphoma].
    Ishige K; Matsue K; Tsukuda K; Sakai C; Takagi T
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):2037-40. PubMed ID: 1417012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A rare thyroid tumor].
    Tabareau F; Ragage F; Berger F; Berger N; Guterman R; Bruch JF
    Ann Pathol; 2010 Apr; 30(2):148-50. PubMed ID: 20451076
    [No Abstract]   [Full Text] [Related]  

  • 36. A long-lasting third complete remission after second autologous transplant followed by maintenance treatment with rituximab in a patient with diffuse large cell non-Hodgkin's lymphoma.
    Ataergin S; Arpaci F; Beyzadeoglu M; Safali M; Ozet A
    Am J Hematol; 2006 Dec; 81(12):986-7. PubMed ID: 16886214
    [No Abstract]   [Full Text] [Related]  

  • 37. Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.
    Mandigers CM; Verdonck LF; Meijerink JP; Dekker AW; Schattenberg AV; Raemaekers JM
    Bone Marrow Transplant; 2003 Dec; 32(12):1159-63. PubMed ID: 14647270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained complete remission following a combination of very low intensity chemotherapy with rituximab in an elderly patient with Burkitt's lymphoma.
    Cohen Y; Amir G; Rachmilewitz EA; Polliack A
    Haematologica; 2002 Jan; 87(1):ELT04. PubMed ID: 11801488
    [No Abstract]   [Full Text] [Related]  

  • 39. High-dose therapy for follicular lymphoma revisited: not if, but when?
    Lister TA
    J Clin Oncol; 2003 Nov; 21(21):3894-6. PubMed ID: 14517186
    [No Abstract]   [Full Text] [Related]  

  • 40. Combination chemotherapy and rituximab.
    Czuczman MS
    Anticancer Drugs; 2001 Jun; 12 Suppl 2():S15-9. PubMed ID: 11508932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.